Custom content for GRAIL by studioID

How Mercy Successfully Implemented Multi-Cancer Early Detection (MCED) Testing

Mercy, one of the 25 largest U.S. health systems, is continually seeking out new technologies and solutions to expand the potential for early cancer detection and management. When this health system added the first-of-its-kind Galleri^® multi-cancer early detection (MCED) test, which detects a signal shared by 50+ types of cancer,¹ the organization rolled out a campaign carefully designed to enable successful testing—and revolutionize cancer screening in its communities.

After reading this case study, you’ll understand how Mercy achieved strategic and operational excellence with the new test — and 6 best practices for adding MCED testing to your health system, including:

Creating an awareness campaign that meets patients where they are
Identifying at-risk patients who could benefit from MCED testing
Prioritizing provider education
Building a seamless patient experience

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

References

1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177. doi: 10.1016/j.annonc.2021.05.806.

For Important Safety Information, visit https://www.galleri.com/safety-information.

First Name *

Last Name *

Work Email *

Company Name *

Job Title *

Company Revenue *

Company Type *

Job Level *

State *

Dive Publication